Colorectal Cancer

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.

The BREAKWATER trial found that encorafenib and cetuximab with mFOLFOX6 chemotherapy generated an ORR of 60.9% in BRAF V600E–mutated metastatic colorectal cancer.

Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer treated in the BESPOKE trial.

Updated results support nivolumab/ipilimumab as a standard of care in patients with MSI-H or dMMR metastatic colorectal cancer.

The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.

No differences in oncologic outcomes occurred between mandatory TME or selective WW strategy in rectal cancer responders to neoadjuvant therapy.

Synchronous metastatic status does not appear to affect survival among patients with resected BRAF V600E-mutated metastatic colorectal cancer.

Trastuzumab/pertuzumab elicited similar efficacy and fewer high-grade AEs vs cetuximab/irinotecan in RAS/BRAF wild-type, HER2–positive metastatic CRC.

Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.

Updated efficacy findings from the phase 3 CheckMate-8HW trial also showed fewer grade 3/4 adverse events with nivolumab/ipilimumab vs chemotherapy.

Nivolumab with ipilimumab elicited improvements to progression-free survival in patients with microsatellite instability–high colorectal cancer.

The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.

The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

CytoDyn intends to submit its final study protocol to the FDA, engage a clinical research organization, and complete preparatory work to initiate the phase 2 trial.

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

Medical professionals analyze gaps in current colorectal cancer patient care, with a focus on minimal residual disease testing.

The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.

Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.